NZ742493B2 - A method for altering the functional state of mrna allowing its selective and specific recognition - Google Patents
A method for altering the functional state of mrna allowing its selective and specific recognition Download PDFInfo
- Publication number
- NZ742493B2 NZ742493B2 NZ742493A NZ74249316A NZ742493B2 NZ 742493 B2 NZ742493 B2 NZ 742493B2 NZ 742493 A NZ742493 A NZ 742493A NZ 74249316 A NZ74249316 A NZ 74249316A NZ 742493 B2 NZ742493 B2 NZ 742493B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- mrna
- poly
- oligonucleotides
- specific
- nucleic acid
- Prior art date
Links
- 108020004999 Messenger RNA Proteins 0.000 claims abstract description 147
- 229920002106 messenger RNA Polymers 0.000 claims abstract description 147
- 229920000272 Oligonucleotide Polymers 0.000 claims abstract description 108
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 82
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 81
- 125000005647 linker group Chemical group 0.000 claims abstract description 56
- 230000000295 complement Effects 0.000 claims abstract description 22
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 20
- 229920001681 Heteroduplex Polymers 0.000 claims abstract description 10
- 238000005755 formation reaction Methods 0.000 claims abstract description 7
- 230000004927 fusion Effects 0.000 claims description 115
- -1 poly(vinylalcohol) Polymers 0.000 claims description 56
- 125000003729 nucleotide group Chemical group 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 26
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 16
- 238000011002 quantification Methods 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000002372 labelling Methods 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- 241000229754 Iva xanthiifolia Species 0.000 claims description 7
- 230000000875 corresponding Effects 0.000 claims description 7
- 150000002500 ions Chemical class 0.000 claims description 6
- 239000000126 substance Chemical class 0.000 claims description 6
- GEGPMWUYMRCINJ-DELVFIHMSA-N (3R,4S)-4-hydroxy-3-[(2,2,2-trifluoroacetyl)amino]-2-[(1R,2S)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid Chemical compound OC[C@H](O)[C@@H](O)C1OC(C(O)=O)=C[C@H](O)[C@H]1NC(=O)C(F)(F)F GEGPMWUYMRCINJ-DELVFIHMSA-N 0.000 claims description 5
- 241001367079 Una Species 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000193 polymethacrylate Polymers 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000007385 chemical modification Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- 206010049460 Abasia Diseases 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 229920002873 Polyethylenimine Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 238000007374 clinical diagnostic method Methods 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 150000004676 glycans Polymers 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 2
- 229920001888 polyacrylic acid Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 150000004804 polysaccharides Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 230000002452 interceptive Effects 0.000 abstract description 8
- 230000001965 increased Effects 0.000 abstract description 5
- 230000000692 anti-sense Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 230000002194 synthesizing Effects 0.000 description 13
- 230000003993 interaction Effects 0.000 description 10
- 230000001225 therapeutic Effects 0.000 description 10
- 210000004881 tumor cells Anatomy 0.000 description 10
- 230000004075 alteration Effects 0.000 description 9
- 230000001364 causal effect Effects 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000036961 partial Effects 0.000 description 8
- 230000001093 anti-cancer Effects 0.000 description 7
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- LLKYUHGUYSLMPA-UHFFFAOYSA-N Phosphoramidite Chemical compound NP([O-])[O-] LLKYUHGUYSLMPA-UHFFFAOYSA-N 0.000 description 5
- 230000002068 genetic Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000006011 modification reaction Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 210000004027 cells Anatomy 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 230000001808 coupling Effects 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 3
- 230000001809 detectable Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000771 oncological Effects 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 150000004713 phosphodiesters Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-Propanediol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- 102100015500 BRD4 Human genes 0.000 description 2
- 101700009767 BRD4 Proteins 0.000 description 2
- 102000008147 Core Binding Factor beta Subunit Human genes 0.000 description 2
- 108010060313 Core Binding Factor beta Subunit Proteins 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- AQSJGOWTSHOLKH-UHFFFAOYSA-N Phosphite Chemical compound [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 230000001588 bifunctional Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 102000025475 oncoproteins Human genes 0.000 description 2
- 108091008124 oncoproteins Proteins 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible Effects 0.000 description 2
- AVJBELCJSGWQNV-UHFFFAOYSA-O rhodamine B 6-isothiocyanate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC(N=C=S)=CC=C1C(O)=O AVJBELCJSGWQNV-UHFFFAOYSA-O 0.000 description 2
- 230000001743 silencing Effects 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tBuOOH Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GBBJBUGPGFNISJ-KNCQCYAQSA-N (1S)-(+)-(10-Camphorsulfonyl)oxaziridine Chemical compound C1S(=O)(=O)N2O[C@@]32C[C@H]2C(C)(C)[C@]13CC2 GBBJBUGPGFNISJ-KNCQCYAQSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- XGDRLCRGKUCBQL-UHFFFAOYSA-N 1H-imidazole-4,5-dicarbonitrile Chemical compound N#CC=1N=CNC=1C#N XGDRLCRGKUCBQL-UHFFFAOYSA-N 0.000 description 1
- WCVOGSZTONGSQY-UHFFFAOYSA-N 2,4,6-Trichloroanisole Chemical compound COC1=C(Cl)C=C(Cl)C=C1Cl WCVOGSZTONGSQY-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- WNVRHTVLVPXIGY-UHFFFAOYSA-N 2-ethylsulfanyltetrazole Chemical compound CCSN1N=CN=N1 WNVRHTVLVPXIGY-UHFFFAOYSA-N 0.000 description 1
- 102000005906 Anaplastic Lymphoma Kinase Human genes 0.000 description 1
- 108010005474 Anaplastic Lymphoma Kinase Proteins 0.000 description 1
- 235000018906 Bauhinia malabarica Nutrition 0.000 description 1
- 244000300022 Bauhinia malabarica Species 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- FENPYOFIQFTMRH-UHFFFAOYSA-N C(Sn1ncnn1)c1ccccc1 Chemical compound C(Sn1ncnn1)c1ccccc1 FENPYOFIQFTMRH-UHFFFAOYSA-N 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N Dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108020004388 MicroRNAs Proteins 0.000 description 1
- 108091007519 PML-RARA Proteins 0.000 description 1
- 102100009871 RBM15 Human genes 0.000 description 1
- 101700005138 RBM15 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241001243925 Sia Species 0.000 description 1
- 102100010276 TAF15 Human genes 0.000 description 1
- 108060008047 TAF15 Proteins 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N Threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 229960004319 Trichloroacetic Acid Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N Trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N dilactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 229920001239 microRNA Polymers 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 201000009500 myxoid chondrosarcoma Diseases 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000005866 tritylation reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
The invention relates to a method of altering the functional state of any mRNA enabling its selective and specific recognition and subsequent selective manipulation. The invention describes a universal principle for increasing the specificity and selectivity of molecular target recognition at the level of nucleic acids. The principle of the specific and selective recognition of nucleic acids is based on simultaneous complementary recognition/interference of two or more target sequences by two or more short sequence-specific oligonucleotides. Said oligonucleotides are mutually interconnected by a size-specific polymeric linking moiety, the length of which is adjusted to the mutual distance between the target sequences and the target nucleic acid, wherein targeting of said oligonucleotides results in the formation of a stable heteroduplex. Such a method of nucleic acid recognition through specific recognition of well-defined sequences of the nucleic acid that are spaced from each other by a defined distance, minimizes the probability of stable binding of the interfering construct to inadvertent nucleic acids, thereby dramatically increasing the selectivity of recognition of the targeted nucleic acid. vel of nucleic acids. The principle of the specific and selective recognition of nucleic acids is based on simultaneous complementary recognition/interference of two or more target sequences by two or more short sequence-specific oligonucleotides. Said oligonucleotides are mutually interconnected by a size-specific polymeric linking moiety, the length of which is adjusted to the mutual distance between the target sequences and the target nucleic acid, wherein targeting of said oligonucleotides results in the formation of a stable heteroduplex. Such a method of nucleic acid recognition through specific recognition of well-defined sequences of the nucleic acid that are spaced from each other by a defined distance, minimizes the probability of stable binding of the interfering construct to inadvertent nucleic acids, thereby dramatically increasing the selectivity of recognition of the targeted nucleic acid.
Description
A method for altering the functional state of mRNA allowing its selective and specific recognition
Field of the Invention
The ion relates to alteration of the functional state of any nucleic acid enabling its specific and ive
recognition and subsequent selective manipulation. The present solution is fully universal and accessible in
fields such as biotechnology, molecular biology, virology, medicine, etc. The invention has direct
applicability and broad therapeutic potential most preferably in the field of oncology, but it is not restricted
to this particular area.
Background of the Invention
In the view of the t state of the art, unlike other, chemically similar constructs, the solution described
in the present invention is designed with a diametrically different objective.
The bivalent system described in nt (Moeller, Udesen, 2011) ents
a multifunctional construct for simultaneous interaction of the linked oligonucleotides with two separate
target nucleic acids in order to saturate their binding sites and modulate thus their biological function. Since
each oligonucleotide recognizes different target nucleic acid molecule, the construct itself principally
functions in the same way as standard antisense ucleotide (with respect to the individual target nucleic
acid molecules) and by no means increases the selectivity of their recognition.
Analogously, the conjugate of antisense oligonucleotides described in document (Agrawal
et al., 2011) is ed to recognize two nucleic acid molecules (either identical or different), while similarly
to document (Moeller, Udesen, 2011), recognizes the target nucleic acid molecules
individually (i.e., via a single antisense ucleotide). Hence the document does not address the issue of
their selective recognition.
Other chemically similar constructs described in documents (Kandimalla et al., 2009),
(Epstein et al., 2005), (Zamore et al., 2005), (Agrawal
et al., 2004) were designed for immunoregulation, to enhance their cellular uptake, miRNA recruiting and
stimulatory purposes, respectively. However, none of them solves the problem of selective
recognition of target nucleic acid les.
In all these cases, the described constructs represent only a kind of “superior”, multivalent form of the
cting molecule, moreover that is designed to solve diametrically different issue, which is unrelated to
the present solution. The fundamental differences thus lie in the fact that while the existing constructs do not
solve the promiscuity of nse oligonucleotides, the present invention provides a solution to this problem.
While the current scientific dges in this field are directed to a treatment of oncological diseases it is
important to note that fusion genes characteristic exclusively to tumor cells are causal in many tumor disease
(leukemias, lymphomas, sarcomas, etc.) and can be certainly ered as a prospective target for anticancer
y. The unique ce of fusion nucleic acid allows for specific and selective ing of tumor cells
t therapeutic intervention in healthy cells. Anticancer therapies based on the interference of therapeutic
agents with c acids thus can be directed against causal fusion nucleic acids and thus to achieve
therapeutic effect exclusively in tumor cells. In the context of nse strategies it means targeted silencing
of fusion genes via erence with the fusion mRNA, thereby preventing the synthesis of causal fusion
proteins.
The issue of insufficient specificity of these antisense strategies (in the terms of binding specificity of
therapeutic agents to the target sequence of mRNA, their binding affinity to the target mRNA and binding
energy with the target mRNA) has been solved primarily by chemical modifications of the therapeutic agents,
e. g. by chemical modification of ribose and/or phosphodiester backbone (Pirollo, Rait et al., 2003; Stahel,
Zangmeister—Wittke, 2003; Jansen, Zangemeister—Wittke, 2002). Despite this, a final on has not yet been
fied, since modified therapeutic agents are not sufficiently specific and ive, and they cause
silencing of therapeutically off-target genes (Burnett, Rossi, 2012). This consequently ces the
expression of non-targeted proteins resulting in s clinical side effects with negative impact on patient
y of life.
With respect to the principle of target mRNA recognition, the application of a single therapeutic, sequence-
specific oligonucleotide which binds to a c region of the target mRNA represents a commonly used
rd of nse strategies. In case of fusion mRNA this specific region is most commonly the site of the
direct fusion ofthe two individual fusion partners s et ai, 2007; Rangatia, Bonnet, 2006; Rapozzi et al.,
2006; Scherr et al., 2005; Scherr et al., 2003; Tanaka et al., 1997). The published data however clearly
indicate to the fact that despite a significant improvement in the physico-chemical properties of antisense
therapeutic agents, the application of a single interfering oligonucleotide has not resolved hitherto the required
progress in the issue of non-specific binding of antisense oligonucleotides to rtent mRNA molecules
(Summerton et al., 2007).
The current state of the art hence still faces the ental challenge that is the specificity and selectivity of
the eutic effect exclusively towards the primary target. A real progress in anticancer strategies thus does
not lie in the development of new therapeutic agents per se, but in the development of systems that allow
ive therapeutic action.
The limitation in terms of insufficient specificity and selectivity of ncer strategies is solved by the
present invention that represents a universal on for any therapeutic strategy that is based on interference
with nucleic acids. The principle of specific and selective recognition of a target nucleic acid together with the
principle of selective action is described and explained via targeted interference with causal fusion genes,
directly implementing the present invention into anticancer antisense strategies.
In all of the referred patents and publications the term "specificity" strictly refers to the complementary base
pairing of the oligonucleotide and target sequenceof nucleic acid, i.e. specificity = complementarity; whereas
in the present invention the term "specificity" refers to complementary recognition and binding to only
one defined target nucleic acid, 1'. e. specificity = ive recognition of the target nucleic acid.
The present invention is hence clearly distinct from the existing antisense systems ed for controlled
intervention of nucleic acids. In other words, the present invention represents a principally innovative solution.
Brief Summary of the Invention
The insufficient specificity stemming from sequence homology to the target c acid, e. g. target mRNA, is
effectively addressed by altering of functional state of the target mRNA enabling its selective and specific
recognition and subsequent selective intervention, manipulation, detection, quantification, labeling, pre-
targeting and g, wherein the mRNA is being targeted by a construct sing at least two sequence-
ic oligonucleotides that are ly interconnected through a size-specific polymeric moiety the
length of which defines their mutual distance, wherein each of the sequence-specific oligonucleotides targets
a pre-defined target sequence of the mRNA resulting in a stable heteroduplex and through this alteration this
mRNA is ively and specifically recognized. The ic and selective recognition of c acid
subsequently can be used for selective therapeutic intervention when the transfer of genetic information
coded by the nucleic acid is interrupted, or for diagnostic and research purposes.
By this alternation, defined sequences of nucleic acids are specifically recognized, wherein these sequences
have to be at a precisely defined distance from each other. In the case of simultaneous recognition of defined
sequences at defined distance from each other, the interfering system designed for the particular l
distribution of target ces forms a thermodynamically preferred and tically stable bond with the
target c acid. This principle of recognition minimizes the probability of non-specific interaction and
stable binding to inadvertent nucleic acids and hence ed interference with nucleic acids outside the
primary target is dramatically decreased.
The described principle of nucleic acid recognition dramatically increases the specificity and selectivity of
interference with one single, particular ed defined nucleic acid. The described principle is fully
universal and it is not restricted only to a mutual interconnection of two sequence-specific oligonucleotides,
i.e. it enables purposeful interconnection of any number of oligonucleotides (n ≥ 2) through a corresponding
number of terfering polymeric linking moieties (n ≥ 1), all with respect to the final application
ion.
In a preferred embodiment of the invention, when the target mRNA is a fusion mRNA, each of the specified
sequences is located on the respective fusion partner and the interfering system is targeted exclusively
towards the fusion nucleic acid that directly ensures selective therapeutic action solely in tumor cells.
Moreover, since the antisense systems are able to have an effect in all cells comprising the target mRNA, the
present invention brings the prospect of curative therapy, since its implementation allows selective
therapeutic targeting of tumor stem cells. By the other words the described innovation brings the hope for
full and permanent curing of the oncological disorder.
In the context of anticancer antisense gies directed to intervention of fusion genes, this principle enables
stable interference with the targeted fusion mRNA solely only in the case, when both of the complementary
sequences of the individual fusion partners, which furthermore are at a precisely d distance from each
other, are recognized. By this means the specificity and selectivity of erence is significantly increased,
whilst the probability of non-specific stable interaction with partially gous sequences is excluded. In
the absence of aneous recognition of both of the complementary sequences, i.e. in the case of unwanted
interaction with inadvertent mRNA, partial interaction of such system with the non-targeted mRNA is
energetically unstable and results in spontaneous disconnection (Dias, Stein, 2002).
The application of the present invention in medicine is demonstrated via antisense systems ed for
anticancer therapy with the y aim of selective intervention of causal fusion genes. In the context of
oncological diseases characterized by the ce of fusion genes it means selective targeting ively
of impaired cells that maximizes therapeutic intervention in the primary target by a fully revolutionary
manner. In the field of oncology the present invention represents a revolutionary tool for intervening
exclusively tumor cells (i.e. without intervention in healthy cells).
Detailed Description of the Invention
The present solution that is the method of altering the functional state of any mRNA enabling its selective and
specific ition and subsequent selective intervention, lation, detection, quantification, labeling,
pre-targeting and sorting of this mRNA, is proposed to increase the specificity and selectivity of targeting of a
particular nucleic acid, and altogether with the specified ation field (e.g. controlled inhibition of causal
fusion genes; detection of presence and quantification of nucleic acids; nucleic acid labeling; pre- targeting
and sorting of nucleic acids) forms integral and inseparable parts of the invention, by which the subject of
invention is clearly defined. The subject matter of the invention thus involves c and selective targeting
of any particular nucleic acid through simultaneous recognition of its two (or more) specified sequences,
which moreover have to be at a pre-defined particular distance from each other.
From the view of the tiveness, the present invention provides a revolutionary tool increasing the
selectivity and specificity of target nucleic acid recognition allowing its selective intervention, manipulation,
detection, quantification, labeling, pre-targeting and sorting.
Selective recognition of a particular nucleic acid (preferably mRNA) in the described way can be subsequently
utilized for ive eutic intervention of its natural biological function, when alteration of its functional
state prevents the er of encoded genetic information. In this way the mechanism of the transfer of genetic
information from nucleic acid to protein is interrupted, which in the case of fusion mRNA enables direct
suppression of the expression of causal fusion oncoproteins.
Analogously, selective recognition of a particular nucleic acid (preferably mRNA) in the bed way
resulting in alteration of its functional state can be subsequently used for various diagnostic or ch
purposes:
- for a direct detection, visualization, localization and quantification of the recognized nucleic acid
(preferably mRNA) via purposeful incorporation of detectable moieties, e. g. FITC, RITC, isotope P32 into the
primary structure of the sequence-specific oligonucleotides. The use of labeled sequence-specific
oligonucleotides enables quantification of the recognized mRNA in the analyzed sample in situ, in vitro, in
vivo and ex-vivo,
- for purification and sorting of the recognized mRNA from other nucleic acids present in the sed
sample,
- for functional analysis of the particular genes via purposeful incorporation of photo-labile functional
groups into the primary structure of the sequence-specific oligonucleotides enabling reversible alteration of the
functional state of the recognized mRNA.
Terms and definitions
nse system. Unlike the currently used antisense systems for controlled suppression of target mRNAs
(Guo et al., 2013; Burnett, Rossi, 2012; Vaishnaw et al., 2010; Missalidis, 2008; Wang et al., 2003; Clark,
2000), the present invention ates their most significant limitation which is the insufficient specificity
and ivity of y target recognition (i.e. promiscuity of antisense oligonucleotides). The promiscuity
of standard antisense s that is closely linked with the length of the antisense oligonucleotide is
effectively solved by simultaneous erence of two (or more) nse oligonucleotides, complementarily
recognizing the target sequences localized at a precisely defined distance from each other. In the field of
anticancer therapies and ally for controlled suppression of causal fusion genes, the t invention, via
its design and mechanism of target mRNA recognition, represents apilot rto not applied) antisense
system.
Construct. The described construct comprises two (or more) sequence-specific Oligonucleotides which are
mutually interconnected through a size-specific polymeric linking moiety.
Sequence-specific oligonucleotide. Oligonucleotides represents ces which is complementary to the
target nucleic acid (preferably mRNA) or to nucleic acid derivatives. Target nucleic acids are preferably of
human .
Oligonucleotides may be formed by any nucleotides, optionally by chemical derivatives/analogues such as
DNA, RNA, 2'-O-(2-methoxyethyl)—RNA, 2'-O-methyl-RNA, 2'-O-fluoro-RNA, LNA, PNA, morpholino,
INA, FANA, ANA, UNA, HNA, etc., and within the present invention they may be mutually ed either
as blocks of Oligonucleotides with a specific chemical modification or as individual Oligonucleotides
comprising differently modified nucleotides. Both the nucleobases and the sugar-phosphate backbone may be
chemically modified.
: i 5
_ t - o l .
' ' -
- °='i'° o- -oFl) 0= 0‘?‘° 0:2—6 . ase
0 0
ass 3“"
Base 3—6 03° Base 0 0 ass 0 Base i ;
<2 F <2? <3 1 I
; a
l l—sN l : ‘~ :
: 0 .
TNA FANA ANA “NA CeNA GNA l PNA
I . ; . E .
9 o O
_ 9 _
_ _ E
O=Fl’-O 0=l?-0 (Hf—o oar-0 O=|f‘0 : O=$-N\
0 O O 0 i 0
Base R : Slaw Base Base ass ass O ase
0 0 0 0 O :
. k j
NH: l N
R . o : ovo Nl-j/O i :
LNA Bridged Bridged i we
: z : . -
. 9 9 't‘” 9 ° °
— —
=Ff—0Me e o=i|=-Me o:|f—s O=lf- H3 0312— e NH_
. o o o o o o o
‘l Ease ‘l Ease ] Ease B356 B
0 0 356
0 O O 1 358
O E o o E859
1 OH on OH :
OH OH
------------------------
Examples of RNAderivatives
A: modifications of the sugar moiety; B: modifications of the phosphate bond; C: modifications of the sugar-
ate backbone.
In the present invention the first oligonucleotide, second oligonucleotide, optionally other ucleotide
comprise a contiguous sequence of at least 3 nucleotides that is capable of base pairing to the complementary
sequence of target nucleic acid (preferably mRNA), wherein
- tides may be A, I, U, T, C, G or derivatives thereof
— Oligonucleotides may se any mutual combination of nucleotides or derivatives thereof.
Other preferred sequences of Oligonucleotides are at least 4 nucleotides, at least 5, at least 6, at least 7, at least
8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least
18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at
least 28, at least 29, at least 30, no more than 30, no more than 29, no more than 28, no more than 27, no more
than 26, no more than 25, no more than 24, no more than 23, no more than 22, no more than 21, no more than
, no more than 19, no more than 18, no more than 17, no more than 16, no more than 15, no more than 14,
no more than 13, no more than 12, no more than 11, no more than 10, no more than 9, no more than 8, no
more than 7, no more than 6, no more than 5, no more than 4, no more than 3 nucleotides long.
The preferred length of the oligonucleotides (individually) is between 10 and 25 nucleotides.
Each of the oligonucleotides within one construct recognizes different complementary sequences of any but
single defined target nucleic acid (preferably mRNA).
The length of ucleotides within one present construct may vary with respect to the particular
application. A stronger interaction with the target nucleic acid may be achieved by a prolongation of the
ucleotide length. On the other hand, prolongation of the oligonucleotides may impair their
bioavailability and cellular internalization. However, since the present invention comprises two (or more)
oligonucleotides in ation (cooperative simultaneous binding to the target nucleic acid), it is le
to use shorter oligonucleotides, preferably ting of less than 17 nucleotides.
Size-specific ric linking moiety. The sequence-specific oligonucleotides are mutually interconnected
via a size-specific ric linking moiety through covalent bond, maintaining the 5' to 3' orientation of all
the consecutively onnected oligonucleotides. The polymeric linking moiety is attached to the 5' end of
first oligonucleotide and the 3' end of second oligonucleotide , wherein the ucleotides are linked by
said polymeric g moiety.
The polymeric linking moiety may consist of any sequence and number of nucleotides (or nucleotide
derivatives/analogues), preferably between 3 and 50 nucleotides (in any of their combination). As well as the
polymeric linking moiety may consist of abasic units, in which case the linking moiety is just a sugarphosphate
or ally modified backbone.
The polymeric linking moiety may be covalently attached to the nucleobase or to the sugar-phosphate
backbone of the oligonucleotides.
The polymeric linking moiety may e.g. be a polypeptide, polysaccharide, saturated or unsaturated
hydrocarbon (C2-C40), preferably a water soluble natural or synthetic polymer though.
In a preferred ment, the polymeric linking moiety comprise a non-nucleotide polymer such as
poly(meth)acrylate or ed eth)acrylate (preferably poly(ethyleneoxy) and 2(N,N-
dimethylamino)ethyl (meth)acrylate), poly(vinylalcohol), poly(vinylpyrrolidone), poly(ethylene glycol),
crylamide), poly(oxazoline), poly(ethyleneimine), poly(alkyleneoxide), lactone-based polymer,
poly(acrylic acid), poly(lactide acid), poly(glycolic acid), poly(propylene), tyrene), poly(olefin),
poly(amide), poly(cyanoacrylate), poly(imide), poly(ethylene terephtalate), poly(tetramethylene glycol),
poly(urethane), as well as a mutual combination thereof or ation of other natural or synthetic rs
(Kadajji, Betageri, 2011).
The length of the polymeric g moiety may be adjusted according to the specific application of the
construct. The length of the polymeric linking moiety is preferably adjusted to the mutual distance between
the target sequences of the target nucleic acid, preferably an mRNA. In case that the complementary
sequences are up to 20 nucleotides far from each other, the final length of the size-specific polymeric linking
moiety may be between 10-100 angstrom based on the distance between nucleotides in a linear, fully
extended nucleic acid. The length of the polymeric linking moiety is not restricted and may be freely adjusted
according to the final application. It is generally preferred that the polymeric linking moiety is no more than
1000 angstrom in
length, no more as 900, 800, 700, 600, 500, 400, 300, 200 or 100 angstrom in length. It is also preferred that
the polymeric linking moiety is at least 5 angstrom in length, such as 10, 15, 20, 25, 30, 35, 40 or 45 angstrom
in .
Preferred ranges of the size-specific ric linking moiety are between 5 and 1000 angstrom, between 10
and 800 angstrom, between 20 and 500 angstrom, between 20 and 200 angstrom, between 10 and 1000
angstrom and n 20 and 80 angstrom.
Synthesis
Sequence-specific oligonucleotides. The chemical sis of ce-specific oligonucleotides is carried
out on a solid support using the phosphoroamidite method, i.e. via consecutive oligomerization of individual
monomers derived from protected 2'-deoxynucleosides (dA, dC, dG, dT), ribonucleosides (A, C, G, U) or
other ally modified sides, while both their particular selection and sequence order depend on
the final application. The synthetic cycle involves step-wise conjugation of dual nucleosides to the
growing oligomer in the order corresponding to the sequence complementary to the target nucleic acid
(preferably mRNA). When completed, the sequence-specific oligonucleotide is released from the solid
support to the solution, prepared for conjugation with the size-specific linking moiety.
Synthesis of RNA, DNA oligonucleotides.
Synthesis cycle. The sis of size-specific oligonucleotides proceeds step-wise in the 3' to 5' direction
when one nucleotide is added to the growing oligomer per synthesis cycle until the desired sequence is
obtained (Greco, Tor, 2007).
Step 1: De-tritylation (removal of protecting group)
The dimethoxytrityl (DMT) protecting group is removed by a solution of an acid, e.g. 2% trichloroacetic acid
or 3% dichloroacetic acid, in an inert solvent (dichloromethane or toluene).
Step 2 and 3: Activation and Coupling (conjugation of nucleosides)
0,02-0,2M solution of nucleoside phosphoramidite in acetonitrile is activated by 0,2–0,7M solution of an
acidic azole catalyst i.e. 1H-tetrazole, 2-ethylthiotetrazole, 2-benzylthiotetrazole, 4,5-dicyanoimidazole, or
other similar compounds (Wei, 2013). The activated phosphoramidite in 1,5 – 2,0-fold excess over the
support-bound oligonucleotides is then reacted with the starting solid t (first coupling) or a supportbound
oligonucleotide precursor (following couplings). The 5'-hydroxy group reacts with the activated
phosphoramidite moiety of the ng nucleoside phosphoramidite to form a phosphite er linkage.
Upon the completion of the coupling reactions, any unbound reagents and by-products are removed by
washing.
Step 4: Oxidation
The newly formed tri-coordinated phosphite triester linkages are subsequently ed with iodine and water
in the presence of weak bases (pyridine, lutidine, or collidine) into a tetra-coordinated ate triester.
Oxidation may be carried out under anhydrous conditions using tert-butyl hydroperoxide (Alul et al., 1991),
or eventually using (1S)-(+)-(10-camphorsulfonyl)-oxaziridine (Manoharan et al., 2000).
Step 5: Capping.
The solid support-bound material is treated with a mixture of acetic ide and ylimidazole.
After termination of the coupling and oxidation on, a small proportion of the solid support-bound 5'-
OH groups (0,1 to 1%) remains unreacted and needs to be ently blocked, e.g. by acetylation, in order
to prevent the formation of ucleotides with an internal base deletion commonly referred to as (n-1)
shortmers.
Step 6: Cleavage
Cleavage of the oligonucleotide from the solid support and de-protection is carried out using concentrated
ammonium hydroxide.
Synthesis of RNA, DNA oligonucleotides with phosphorothioate backbone
Modified oligonucleotides, wherein one of the oxygen atoms in the phosphodiester backbone is replaced with
a sulfur atom, are sized ously to common RNA and DNA ucleotides (for details see the
Synthesis cycle section). The difference lies in the replacement of the oxidation step with sulphurization.
Synthesis of LNA oligonucleotides
Modified oligonucleotides, in which the ribose is modified by a covalent bridge between the 2'-O and 4'-C
atoms, are synthesized according to Obika et al. (1997) and Koshkin et al. (1998).
Synthesis of PNA oligonucleotides
Modified oligonucleotides, in which the sugar-phosphate backbone is formed by repeating N-(2-aminoethyl)-
glycine units mutually linked via a peptide-like bond, are synthesized according to n et al. (1991).
Synthesis of Morpholino oligonucleotides
Modified oligonucleotides, in which the nucleobase is linked to a morpholine ring and interconnected via a
orodiamidate linkage, are synthesized according to Summerton and Weller (1991, 1993b, 1997).
Synthesis of GNA oligonucleotides
Modified oligonucleotides, in which the sugar-phosphate backbone is constituted by repeating glycol
moieties interconnected via a phosphodiester linkage, are sized according to Ueda et al. (1971) and
Cook et al. (1995, 1999).
Synthesis of TNA oligonucleotides
Modified oligonucleotides, in which the sugar-phosphate backbone is constituted by threose instead of ribose,
are synthesized according to Chaput and Szostak (2003).
Size-specific polymeric linking moiety. Chemical sis of the size-specific linking moiety is performed
using the common methods of organic and polymer chemistry, which allow to control the final molecular
weight and hence the final length of the polymer chain, e.g. atom transfer radical polymerization
(Matyjaszewski, Xia, 2001). The pecific polymeric g moiety may be a bifunctional moiety (i.e.
functionally modified at both of its ends) to enable subsequent attachment to both of the sequence-specific
oligonucleotides into a final, 5' to 3' oriented construct.
The bifunctional size-specific polymeric linking moiety is preferably formed by non-nucleotide polymers
such as polyethylene glycol (PEG), however, the resulting uct is not restricted to this particular type of
polymeric moiety (for a detailed description of possible structural variants see the ed description of the
Invention n). PEGylation of nucleotides and the s of ation of PEGylated nucleotides have
been bed previously by Jäschke et al. (1994) and Fischer et al. (2008).
atively, if the size-specified polymeric linking moiety is not directly synthetized, it is le to use
a cially available polymer moieties such as 17-O-DMT-hexaethyleneoxideO-phosphoramidite, 8-
DMT-O-triethyleneoxideO-phosphoramidite, 6-DMT-hexane diolO-DMT-phosphoramidite, or 1,3-
propanediol, phosphoramidite and others.
Construct. The synthesis of the final construct is carried out by consecutive conjugation of the size-specific
polymeric linking moiety with the first ce-specific oligonucleotide and subsequent attaching the
resulting precursor to the second sequence-specific oligonucleotide, e.g. via "click" chemistry (Presolski et
al., 2011; Besanceney-webler et al., 2011; Bowman, Hoyle, 2010).
Brief Description of the Drawings
Figure 1 depicts the general principle of highly specific interaction of the interfering system with the target
sequence of the c acid via two sequence-specific oligonucleotides being mutually interconnected
through a size-specific linking moiety. The proposed principle is universal and adjustable so that it enables
purposeful onnection of any number of sequence-specific oligonucleotides (n ≥ 2) via a corresponding
number of non-interfering size-specific linking moieties (n ≥ 1).
Figure 2 depicts the highly specific interaction of the interfering system with the target sequences of fusion
mRNA via two sequence-specific oligonucleotides mutually interconnected through a size-specific g
moiety. Each of the sequence-specific oligonucleotides binds to the corresponding sequence of the fusion
partners.
The solution bed in this invention can be considered as universally applicable for selective and ic
recognition of any target nucleic acid, ably fusion mRNA. In the t of antisense systems, when
the target nucleic acid is a fusion mRNA (its presence unequivocally characterizes and distinguishes tumor
cells from healthy ones), the present invention enables selective recognition and targeting solely of the tumor
cells. The innovation in the form of ed selectivity and specificity of recognition solely of the target
nucleic acid, preferably a fusion mRNA, allows controlled intervention of target fusion genes.
e 1. Selective and specific recognition of the BCR-ABL fusion mRNA in chronic myelogenous
leukemia or Ph+ acute blastic leukemia, or other neoplasia where BCR-ABL fusion mRNA is present,
using the present invention.
The proposed construct selectively and specifically recognizes the BCR-ABL mRNA in a way when the first
sequence-specific oligonucleotide targets the sequence of BCR and the second oligonucleotide targets the
sequence of ABL, whilst both of the oligonucleotides are mutually interconnected through a size-specific
polymeric linking moiety. It is also possible to apply more than two sequence-specific oligonucleotides, when
each of them targets either the BCR or ABL, wherein each of the fusion partners is targeted by at least one
oligonucleotide. The sequence-specific oligonucleotides are ly interconnected through
a corresponding number of polymeric linking moieties. A stable, thermodynamically and energetically
preferable complementary interaction n the construct and the targeted BCR-ABL mRNA is formed
only in the case, when each of the target sequences is fully recognized and moreover spaced from each other
by a certain distance defined by the pecific polymeric linking moiety. By this means the probability of
stable binding of the construct to partially homologous mRNAs is minimized that prevents a stable
ention with inadvertent mRNA molecules. With respect to the fact, that fusion BCR-ABL mRNA is
exclusively present in
tumor cells, the described principle of BCR-ABL mRNA recognition s in preferential and stable
intervention solely in tumor cells, thereby to a selective recognition and targeting of tumor cells.
The ces of individual sequence-specific oligonucleotides within the construct are complementary to the
target sequences of individual fusion partners BCR, ABL. The target sequences of BCR, ABL may be optional
referring to the primary sequence of the fusion BCR-ABL mRNA, however in a preferred embodiment the
distance of the target sequences from the fusion breakpoint site is no more than 100 nucleotides, irrespective
of the particular fusion BCR-ABL mRNA variant.
‘ acgttcc cctc tgactatgag cgtgcagagt ggagggagaa catccgggag
cagcagaaga agtgtttcag aagcttctcc tccg tggagctgca gatgctgacc
aactcgtgtg tgaaactcca gactgtccac agcattccgc tgaccatcaa agaa
gcccttcagc taqg_g§gtgacttt gagcctcagg gtctgagtga aqccgctcgt
tggaactcca aqgaaaacct tctcgctgga cccagtgaaa atgaccccaa ccttttcgt
tatg tqgc cagtggagat aacactctaa gcataactaa aggtgaaaag
Partial primary ce of fusion BCR-ABL mRNA (GenBank: AJ311467.1); BCR — black, ABL — grey; target sequences are
underlined.
linking moiety (8 nt gap)
3' GTTATTCCTTC ———————————-———f GTCGCCGGTCATCGTAG 5’
Example of the construct designed for selective and specific recognition of BCR-ABL mRNA. The complementary oligonucleotide to
BCR (17 nt) and ABL] (l7nt) are shown in black and grey, respectively.
Analogously to Example 1, Examples 2-7 in an abridged form as well as the list of other fusion mRNAs are
given below.
Exampte 2. Selective and specific recognition of the AMLI-ETO fusion mRNA in acute myeloid leukemia M2
or other neoplasia where AMLI-ETO fusion mRNA is present, using the present ion.
‘ atcaaaa tcacagtgga tgggccccga gaacctcgaa athtactga gaaqcactcc
acaatgccag actcacctgt gaag acgcaatcta ggctgactcc tccaacaatg
ccacctcccc caactactca aggagctcca agaaccagtt catttacacc gacaacgtta
actaai:ggca cgagccattc tcctacagcc ttgaatggcg ccccctcacc acccaatggc
Partial primary sequence of fusion AMLI-ETO mRNA (GenBank: S78158.1); AMLI— black, ETO — grey; target sequences are
underlined.
linking moiety (17 nt gap)
3’ TAGTGTCACCTACCCG ---------------- GCATGACTCTTCGTGAGG 5'
Example of the uct designed for ive and specific recognition ofAMLI-ETO mRNA. The complementary oligonucleotide to
AMLI (16 nt) and ETO (18nt) are shown in black and grey, tively.
:Example 3. Selective and specific recognition of the CBFB—MYHII fusion mRNA in acute myeloid leukemia
M4 or other sia where CBFB-MYHI 1 fusion mRNA is present, using the present ion.
‘ tttgaag atagagacag gtctcatcgg gaggaaatgg agejtoaag3__§ggg§gg_ggtc
acagg‘gatgc ttaacgaggc Cgagggqaag gccattaagc: tggccaagga crgtggcgtcc
ctcag‘ttccc agctccagga cacccaggag tt
Partial primary sequence of fusion CBFB-MYH] 1 mRNA (GenBank: AF249897.1); CBFB — black, MYHII — grey; target sequences
are underlined.
linking moiety (12 nt gap)
3' TATCTCTGTCCAGAGTAGCC TTACTTCAACTCTCG 5'
Example of the construct designed for selective and specific recognition of CBFB-MYHI 1 mRNA. The complementary ucleotide
to CBFB (20 nt) and MYHII (15nt) are shown in black and grey, respectively.
Example 4. Selective and specific recognition of the MKLI fusion mRNA in acute myeloid leukemia
or other neoplasia where RBM15-MKL1 fusion mRNA is present, using the present invention.
‘ tccctgt ggggggcaac aaagacaagg ccgg ggtccttcat gccttcccac
cttgtgagtt ctcccagcag ttcctggatt cccctgccaa ggcactggcc aaatctgaag
gagattacct ggtcatgatc cgtg ctttgaaaao tccaqqg ca gagc
agagaaggag cttggagcgg gccaggacag aggactatct caaacggaag attcgttccc
gqccggagag atcggagctg gtcaggatgc acattttgga agagaccth gctgagccar
Partial primary sequence of fusion RBM15-MKL1 mRNA (GenBank: AF364035.1); RBM15 — black, MKLI — grey; target ces
are underlined.
linking moiety (8 nt gap) linking moiety (12 nt gap)
3' CGGTTTAGACTTCT --------- ACCAGTACTAGTAACAG TCAGGTCGGCGTAAAG 5'
Example of the construct designed for selective and specific recognition of REM]5-MKL1 mRNA. The complementary oligonucleotide
to RBMIJ' (14 nt, 17 nt) and MKLI (17 nt) are shown in black and grey, tively.
Example 5. Selective and specific recognition of the P fusion mRNA in acute myeloid leukemia or
other neoplasia where MOZ—CBP fusion mRNA is present, using the present invention.
‘ aaatgaa cttttcccta gagaatactt ccgtcgtttg tcttcgcagg tcag
gtgtcagtcc tcttctaaga ggaagtctaa agatgaagaa gaag agtcagatga
Egctgatgat gggaataact qqgaacacaa qt.“ lit tog acagc Co'ttg-..§git—“ with
gagggcagcc agcc actggagtga ac t agccagcaaa cagagcatgg
tcaacagttt gcccaccttc cctacagata tcaaqaatac ttcagtcacc aacgtgccaa
Partial primary sequence of fusion P mRNA (GenBank: A125 1844. l); MOZ — black, CBP — grey; target sequences are
underhned.
linking moiety (15 nt gap) linking moiety (13 nt gap)
3' TACTTCTCAGTCTACTAC ------ TGACCCTTGTGTTCAGGTA ------- ATCAGTTCGACCTCC 5'
Example of the construct designed for selective and specific recognition ofMOZ-CBP mRNA.' The complementary oligonucleotide to
MOZ (18 nt, 19 nt) and CBP (15 nt) are shown in black and grey, respectively.
Example 6. Selective and specific recognition of the TAFZN-TEC fusion mRNA in myxoid chondrosarcoma
or other neoplasia where TEC fusion mRNA is present, using the present invention.
‘ ttatgat catg attcctatag tcaaaaccag cagtcctatc attcacaaag
ggaaaactac agccaccaca cacaagatat gccctqcotc caagcccaat atagcccttc
ccgtcggggt topaqtta£g_gggcgcagac atacagctcg gaatacacca cggagatcat
gaaccccgac taeaccaagc tgaccatgga ccttggcagc atca cggctacagc
Partial primary ce of fusion TAF2N-TEC mRNA (GenBank: AJ245932.1); TAFZN — black, TEC — grey; target sequences are
underhned.
g moiety (9 nt gap) linking moiety (13 nt gap)
3' GTGTGTGTTC ------ CGCAGGTTCGGGTTATA ——————— GTCCAAGGTCAATACG 5'
Example of the construct designed for selective and specific recognition of TAFZN—TEC mRNA. The complementary oligonucleotides
to TAF2N (16 nt) and TEC (17 nt, 16 nt) are shown in black and grey, respectively.
Example 7. Selective and specific recognition of the UT fusion mRNA in mediastinal carcinoma or
other neoplasia where BRD4-NUT fusion mRNA is present, using the present invention.
‘ gagcgct atgtcacctc ctgtttgcgg aagaaaagga aacctcaagc tgagaaagtt
gatgtgattg ccggctcctc gaag ggcttctcgt cctcagagtc ctcc
agtgagtcca gctcctctga cagcgaagac tccgaaacag Cuggitl—lefllgiifl
gatatgagca cctag tgccgccctg tctccatccc ttcc Ctttctccca
ccaai:ttctq avcccaccaga ccacccaccc agggagccac ctccacagcc catca'tgcct
Partial primary sequence of fusion BRsz-NUTmRNA (GenBank: AY166680.1); BRD4 — black, NUT — grey; target sequences are
underlined.
linking moiety (7 nt gap) linking moiety (7 nt gap) linking moiety (8 nt gap)
3 ' TCTCGAGGTCACTCAGGT —-—~ ACTGTCGCTTCTGAGGCT ---— AGACG'i.‘AAC(—?GCCC'I’GGC ——--
GTACTTTGGATCACGGCG 5 '
e of the uct designed for selective and specific recognition -NUT mRNA. The complementary oligonucleotides
to BRD4 (18 nt, 18 nt) and NUT(18 nt, 18 nt) are shown in black and grey, respectively.
In analogy, it is possible to selectively and specifically recognize the following fusion mRNAs:
fusion PML-RARA mRNA fusion BCM-ILZ mRNA
fusion TEL-AMLI mRNA fusion CEV14-PDGFRB mRNA
fusion TCR-RBTN2 mRNA fusion RBMIS-MKL mRNA
fusion TMPRSSZ-ETS mRNA fusion TRK3 mRNA
fusion NPM-ALK mRNA fusion TFE3-PRCC mRNA
fusion PLZF-RARA mRNA fusion TFE3-ASPSCR1 mRNA
fusion MLL-AF9 mRNA fusion PAX8—PPARG mRNA
fusion DEK-CANmRNA fusion TETI-TP53 mRNA
fusion FUS-ERG mRNA fusion TFEB-ALPHA mRNA
fusion AMLI-MTG mRNA fusion TFE3-PSF mRNA
fusion AMLl-EAP mRNA fusion CHOP-EWS mRNA
fusion NUP98-PMX1 mRNA fusion PAX3-FKHR mRNA
fusion MLL-AFPI mRNA fusion JAZFI-JJAZI mRNA
fusion EA2-HLF mRNA fusion FUS-CREB312 mRNA
fusion MOZ-P300 mRNA fusion TPM3-ALKmRNA
fusion TEL-PDGFRB mRNA fusion CLTC-ALK mRNA
fusion MLL-AFXI mRNA fusion V11 mRNA
fusion EZA-PBXI mRNA fusion EWS-FLII mRNA
fusion MLL-AF6 mRNA fusion AMZI-EVI-J mRNA
fusion NUP98—HOXA9 mRNA fusion ETV6-MN1 mRNA
fusion MLL-AF4 mRNA fusion MLL-ENL mRNA
fusion NUP98-RAP1GDS1 mRNA fusion CALM-AF]0 mRNA
fusion FUS—CHOP mRNA fusion PAX7-FKHR mRNA
fusion SYT-SSXmRNA fusion EWS-CHNmRNA
fusion TCF12-TEC mRNA fusion EWS-WTI mRNA
fusion FE3 mRNA fusion -PDGFB mRNA
fusion TPM4-ALK mRNA
Other applications ofthe present invention are demonstrated via Examples 8-11.
Example 8. Selective and ic eutic intervention to the natural biological function of any mRNA,
when after application of the present invention and alteration of the functional state of the recognized mRNA
the er of genetic information coded by this mRNA is prevented. y, the mechanism of translation
of the genetic information from mRNA to protein is interrupted which in case of a fusion mRNA, such as in
es 1-7, results in direct suppression of the expression of causal fusion oncoproteins.
e 9. Selective and specific detection of any mRNAs and subsequent quantification thereof, when
ce-specific oligonucleotides contain an incorporated detectable label, such as FITC, RITC, P32 isotope,
which after application of the present invention and alteration of the functional state of the recognized mRNA
emits a detectable signal corresponding to the stable duplex.
Example 10. Purification and g of selectively and specifically recognized mRNA from other nucleic
acids present in the ed sample, when the application of the present invention results in the alteration
of the functional state of the recognized mRNA, i.e. a stable heteroduplex with different electrophoretic
ty is formed. Consequently, it is possible to separate the ized mRNAs from other nucleic acids
by applying of an external electric field. Analogously, via purposeful modification of sequence-specific
oligonucleotides with primary antibodies, it is possible to sort the recognized mRNA after application of the
present invention on the basis of its interaction with secondary antibodies.
Example 11. Functional analysis of individual genes, when a y structure of sequence-specific
oligonucleotides contain incorporated photo-labile functional groups enabling reversible change of the
functional state of recognized mRNA. After application of the t invention and alteration of the
functional state of the recognized mRNA it is possible to reverse this effect by application of radiation of
a required wavelength. In this way it is possible to ively and ically study effects of suppression
of gene expression under in situ and in vivo ions.
Definitions of specific embodiments of the invention as claimed herein follow.
According to a first aspect of the invention, there is provided a method for altering of the functional state of
any nucleic acid enabling its selective and specific recognition, and subsequently selective intervention,
manipulation, detection, quantification, labeling, pre-targeting and sorting thereof, wherein, the nucleic
acid is targeted by applying a construct formed by at least two sequence-specific -stranded
oligonucleotides being mutually interconnected through a linking , the length of which is adjusted to
the mutual distance between the target ces of the target nucleic acid, and which defines their mutual
distance, n each of the sequence-specific single-stranded oligonucleotides is targeted to a predefined
target ce of the nucleic acid resulting in the formation of a stable heteroduplex and on the
basis of such alternation the nucleic acid is selectively and specifically recognized, provided said method is
not performed within a human and provided that the linking moiety is not DNA.
According to a second aspect of the invention, there is provided a construct for altering the functional state
of any nucleic acid enabling its selective and specific recognition, and subsequently selective intervention,
lation, detection, quantification, labeling, pre-targeting and sorting thereof, wherein, the uct is
targeting said nucleic acid to form a stable heteroduplex, and wherein the construct comprises at least two
sequence-specific -stranded oligonucleotides being mutually interconnected through a linking moiety,
each of the sequence-specific single-stranded oligonucleotides is targeted to a pre-defined target sequence of
the nucleic acid resulting in the formation of a stable heteroduplex, each of the oligonucleotides within the
one construct recognize different complementary sequences of the target nucleic acid, the length of the
linking moiety is adjusted to the mutual distance between the target sequences of the target nucleic acid and
is between 5 and 1000 angstrom, provided the linking moiety is not DNA.
According to a third aspect of the invention, there is provided a ition comprising a uct according
to the second aspect when used in in vitro diagnostics.
According to a fourth aspect of the invention, there is provided use of a construct according to the second
aspect in the manufacture of a medicament for diagnosing or treating cancer.
Claims (18)
1. A method for altering of the functional state of any nucleic acid enabling its selective and ic recognition, and subsequently selective intervention, manipulation, detection, quantification, labeling, pre-targeting and sorting thereof, wherein, the nucleic acid is targeted by ng a construct formed by at least two ce-specific single-stranded oligonucleotides being mutually interconnected through a linking moiety, the length of which is adjusted to the mutual ce between the target sequences of the target c acid, and which defines their mutual distance, wherein each of the sequence-specific single-stranded oligonucleotides is targeted to a pre-defined target sequence of the nucleic acid resulting in the formation of a stable heteroduplex and on the basis of such alternation the nucleic acid is selectively and specifically recognized, provided said method is not performed within a human and provided that the linking moiety is not DNA.
2. The method according to claim 1, wherein the nucleic acid is any mRNA.
3. The method according to claim 2, wherein any mRNA is a fusion mRNA.
4. The method according to claim 3, wherein each of the fusion partners of the target fusion mRNA is targeted by at least one sequence-specific oligonucleotide.
5. The method according to claim 3, wherein the target sequences are localized not more than 100 nucleotides from the fusion breakpoint site.
6. The method ing to claim 2, wherein the sequences of individual sequence-specific oligonucleotides of the construct are targeted according to the mentarity to individual predefined regions of mRNA.
7. The method according to claim 2, wherein the mRNA is targeted with a construct comprising at least 3 oligonucleotides, each of the oligonucleotides targets a fined target sequence of the individual regions of mRNA, wherein the oligonucleotides are being mutually interconnected through a corresponding number of size-specific linking moieties.
8. The method according to claim 2, n the length of the linking moiety ranges between 5 and 1000 angstrom.
9. The method according to claim 2, wherein the linking moiety is attached to the 5' end of the first oligonucleotide and to the 3' end of the second oligonucleotide.
10. The method according to claim 2, wherein the linking moiety is a polymeric linking moiety.
11. The method according to claim 1, wherein the g moiety comprises a) any sequence and number of nucleotides or tide derivatives/analogues selected from 2'-O-(2- methoxyethyl)-RNA, 2'-O-methyl-RNA, 2'O-fluoro-RNA, LNA, PNA, lino, INA, FANA, ANA, UNA or HNA units, or a combination thereof, wherein the linking moiety may also t of a sugar-phosphate backbone or any chemically modified abasic backbone; b) a polypeptide of any sequence; c) a polysaccharide; d) a saturated or unsaturated hydrocarbon (C 2-C 40); e) a cleotide polymer selected from poly(meth)acrylate or modified poly(meth)acrylate, poly(vinylalcohol), poly(vinylpyrrolidone), poly(ethylene glycol), poly(acrylamide), poly(oxazoline), poly(ethyleneimine), poly(alkyleneoxide), e-based polymer, poly(acrylic acid), actide acid), poly(glycolic acid), poly(propylene), poly(styrene), poly(olefin), poly(amide), poly(cyanoacrylate), poly(imide), poly(ethylene terephtalate), poly(tetramethylene glycol), poly(urethane), or ymers f.
12. The method according to claim 11, n the nucleotides or nucleotide tives/analogues selected from 2'-O-(2-methoxyethyl)-RNA, 2'-O-methyl-RNA, 2'O-fluoro-RNA, LNA, PNA, lino, INA, FANA, ANA, UNA or HNA units, or a combination thereof, comprise between 1 and 50 nucleotides in any combination.
13. The method according to claim 11, wherein the ed poly(meth)acrylate comprises poly(ethyleneoxy) and 2(N,N-dimethylamino)ethyl (meth)acrylate).
14. The method according to claim 1, wherein the length of sequence-specific oligonucleotides is at least 3 nucleotides, wherein they se any nucleotides or chemical derivatives/analogues thereof selected from DNA, 2'-O-(2-methoxyethyl)-RNA, 2'-O-methyl-RNA, 2'O-fluoro-RNA, LNA, PNA, morpholino, INA, FANA, ANA, UNA or HNA units, or a combination f, and may be ly combined either as blocks of oligonucleotides with a specific chemical modification or as individual oligonucleotides consisting of differently modified nucleotides.
15. The method according to claim 1, wherein the length of sequence-specific oligonucleotides ranges between 10 and 25 nucleotides.
16. A construct for altering the functional state of any nucleic acid enabling its selective and specific recognition, and subsequently ive intervention, manipulation, ion, quantification, labeling, pre-targeting and sorting thereof, wherein, the construct is targeting said nucleic acid to form a stable heteroduplex, and wherein the construct comprises at least two sequence-specific single-stranded oligonucleotides being mutually interconnected through a linking moiety, each of the sequencespecific single-stranded oligonucleotides is ed to a pre-defined target sequence of the nucleic acid resulting in the formation of a stable heteroduplex, each of the oligonucleotides within the one uct recognize different complementary sequences of the target nucleic acid, the length of the linking moiety is adjusted to the mutual distance between the target sequences of the target nucleic acid and is between 5 and 1000 angstrom, provided the linking moiety is not DNA.
17. A composition comprising the construct of claim 16, when used in in vitro diagnostics.
18. Use of a construct of claim 16 in the manufacture of a medicament for diagnosing or treating cancer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SKPP50065-2015 | 2015-10-15 | ||
SK50065-2015A SK500652015A3 (en) | 2015-10-15 | 2015-10-15 | A method for altering the functional state of mRNA allowing its selective and specific recognition |
PCT/SK2016/060002 WO2017065696A2 (en) | 2015-10-15 | 2016-10-12 | A method for altering the functional state of mrna allowing its selective and specific recognition |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ742493A NZ742493A (en) | 2021-09-24 |
NZ742493B2 true NZ742493B2 (en) | 2022-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7667033B2 (en) | Compositions and methods for the use of FMOC derivatives in DNA/RNA synthesis | |
Giovannangeli et al. | Oligonucleotide clamps arrest DNA synthesis on a single-stranded DNA target. | |
US8552167B2 (en) | Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing | |
SI2902406T1 (en) | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) | |
WO1992018522A1 (en) | Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences | |
JPH06511155A (en) | 2' modified oligonucleotide with gap | |
JP2004507263A (en) | Antisense oligonucleotides to VR1 | |
JP2009108095A (en) | Oligonucleotide n3'->p5' phosphoramidates: synthesis and compound; hybridization and nuclease resistance properties | |
JPH10512446A (en) | Compositions and methods for treating tumor cells | |
WO2010040091A1 (en) | Novel dna nanostructures that promote cell-cell interaction and use thereof | |
WO2011129494A1 (en) | Nucleolin specific aptamer and use thereof | |
AU691300B2 (en) | Complementary DNA and toxins | |
JP2022097486A (en) | Method for altering functional state of mrna to allow its selective and specific recognition | |
WO2021076574A2 (en) | Fn3 domain-sirna conjugates and uses thereof | |
NZ742493B2 (en) | A method for altering the functional state of mrna allowing its selective and specific recognition | |
WO2021015234A1 (en) | Chimeric molecule, pharmaceutical composition, method for cleaving target nucleic acid, and kit for target nucleic acid cleavage or diagnosis | |
Efimov et al. | Convenient approaches to the synthesis of oligonucleotide macrocycles containing non-nucleotide linkers | |
Dickinson | Mechanism of action of GGA, a targeted oligonucleotide enhancer of splicing developed for the treatment of spinal muscular atrophy | |
Murakami | Artificially Created Nucleic Acids and Peptides/Proteins in Chemical Biology |